Half of vaccines are binned – ‘fridge-free’ versions could change that

Revolutionary Dry-Powder Vaccine Technology Could Eliminate Cold Chain Wastage

Constantvpn.com – A groundbreaking approach to vaccine preservation has shown promising results in early clinical testing, potentially transforming how life-saving immunizations reach communities worldwide. Scientists in the United Kingdom have successfully demonstrated that certain vaccines can be stored as dry powders at room temperature without losing their effectiveness, addressing one of the most persistent challenges in global healthcare delivery.

The Cold Chain Problem

Every year, approximately fifty percent of all vaccines produced globally end up being discarded or wasted. This staggering figure stems primarily from failures in what experts call the “cold chain”—the continuous system of temperature-controlled storage and transportation that keeps vaccines viable from manufacturing facilities to the moment they are administered to patients. When vaccines are exposed to temperatures that are too high or too low, their active components degrade, rendering them useless.

This issue is particularly acute in developing nations and conflict zones where reliable electricity and refrigeration equipment remain scarce. Even in wealthier countries, transportation delays and equipment malfunctions can compromise vaccine integrity before they reach clinics and hospitals.

Resurrection Plants Inspire Innovation

The new technology draws inspiration from nature’s own survival mechanisms. Resurrection plants, which grow in arid regions, have the remarkable ability to dry out completely during droughts and appear entirely lifeless. When rainfall returns, these plants rapidly rehydrate and resume normal biological functions. This resilience is made possible by trehalose, a specialized sugar that protects cellular structures during periods of extreme desiccation.

Stablepharma, a biotechnology company based in the UK, applied this biological principle to vaccine development. Researchers converted a standard liquid tetanus-diphtheria vaccine into a dry powder form using trehalose as a stabilizing agent. The powder remained stable at room temperature for an entire year before being reconstituted with water and administered to trial participants.

“This obviously has potential to remove cold chain dependence, reduce wastage and improve access,” said Prof Saul Faust, director of the NIHR Clinical Research Facility in Southampton.

Clinical Trial Results

The initial trial involved sixty volunteers who received the dry-powder formulation. Early-stage studies indicated that participants developed immune responses equivalent to those produced by conventional refrigerated vaccines. Importantly, the treatment proved safe and well-tolerated across all participants.

Hannah Kedzia was among those who participated in the clinical trial during April 2025, contributing to the growing body of evidence supporting this preservation method.

A more extensive study involving 160 participants is scheduled to begin within the coming months. This expanded trial represents the final research phase before the technology can be fully validated, since the original tetanus-diphtheria vaccine already holds regulatory approval and licensing, eliminating the need for large-scale trials typically required for entirely new vaccine formulations.

Meeting Global Standards

The research aligns with specific targets established by the World Health Organization. The WHO aims to develop vaccines capable of surviving temperatures up to 30 degrees Celsius alongside 75 percent relative humidity—conditions common in many tropical and subtropical regions.

While meeting this benchmark remains the primary objective, preliminary data suggests the Stablepharma formulation may withstand even more extreme conditions. Components of the vaccine successfully survived temperature cycling between minus 20 degrees Celsius and plus 40 degrees Celsius, making it potentially suitable for transport in refrigerated aircraft holds followed by delivery in uncooled trucks through hot climates.

“Reliable and safe fridge-free vaccines could be a game-changer for global health,” stated Dr Bruce Roser, founder of Stablepharma.

Broader Implications

Vaccine wastage occurs for multiple reasons beyond temperature sensitivity. Damaged shipments, expired products, and unused portions from multi-dose vials all contribute to the problem. However, cold chain failures represent a significant portion of preventable losses worldwide.

Prof Sir Jonathan Van-Tam, former deputy chief medical officer for England and current advisor to Stablepharma, brought personal experience to the technology’s potential impact. Having worked extensively in remote field clinics, he recalled the constant anxiety of transporting vaccines in cool boxes across difficult terrain where unpredictable travel times threatened the integrity of temperature-sensitive products.

“I can remember taking out vaccines in cool boxes… doing that on really inhospitable roads where one couldn’t predict getting from A to B in a short period of time and there was always this nervousness about maintaining the cold chain in time to get the vaccines into arms of waiting children.”

Future Applications and Remaining Questions

While the current approach cannot be applied to mRNA vaccines due to their different molecular structure, many existing vaccine types could potentially benefit from trehalose stabilization. The technology may also extend beyond traditional vaccines to include certain medications requiring refrigeration, such as monoclonal antibodies used in treating various conditions.

Prof Tuck Seng Wong, director of the UK-Southeast Asia Vaccine Manufacturing Research Hub, described the findings as “very exciting” and a “significant breakthrough in UK science.” However, he noted that several areas require further investigation, including long-term stability under fluctuating temperatures and performance across more ethnically diverse populations.

The research has been published in eClinicalMedicine, a journal within the Lancet publishing group. Ephrem Tekle Lemango, Unicef’s associate director of immunization, emphasized that immunization remains a “life-saving service that depends on refrigeration,” making this innovation particularly timely for organizations working to expand vaccine access in underserved regions.

As climate change continues to affect transportation infrastructure and energy availability worldwide, technologies that reduce dependence on continuous refrigeration could prove increasingly valuable. The ability to store and transport vaccines without specialized equipment would not only reduce costs but also enable health workers to reach more remote communities with essential immunizations.